PE Tech Report


Like this article?

Sign up to our free newsletter

3i in exclusive negotiations to sell Havea Group to BC Partners

3i Group (3i) and its co-investor Cathay Capital, have entered into exclusive negotiations for the sale of its investment in Havea Group (Havea) to funds advised by BC Partners, alongside Havea’s management team.

Proceeds to 3i will be at a c50% uplift to its 31 March 2022 valuation.
Havea is a European natural healthcare player featuring a unique consumer/patient-centric approach centred on 5 strategic brands: Aragan, Biolane, Densmore, Dermovitamina and Vitavea. The Group and its brands help consumers prevent and treat common health issues with premium natural healthcare products. Powered by innovation and with a focus on sustainability – both at the core of Havea’s DNA – the company enables consumers to improve their quality of life.
3i invested in Havea in 2017 and supported its transformation to become a leader in its sector and double in size reaching €212 million sales in 2021. 
Completion of the transaction remains subject to the information and consultation of the employees’ representative bodies of Havea and to customary regulatory and antitrust approvals. The transaction is expected to close by Q4 2022.

Like this article? Sign up to our free newsletter